Applied Therapeutics, Inc. (APLT)

Market Cap	52.24M
Revenue (ttm)	265,000
Net Income (ttm)	-43.51M
Shares Out	141.58M
EPS (ttm)	-0.30
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,971,386
Open	0.3381
Previous Close	0.3356
Day's Range	0.3381 - 0.3690
52-Week Range	0.2950 - 10.6240
Beta	1.82
Analysts	Buy
Price Target	6.10 (+1,553.12%)
Earnings Date	Aug 6, 2025

About APLT

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company’s lead product candidate is AT-007 that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-C...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 14, 2019
• Employees: 35
• Stock Exchange: NASDAQ
• Ticker Symbol: APLT
• Website: https://www.appliedtherapeutics.com

Financial Performance

In 2024, Applied Therapeutics's revenue was $455,000, a decrease of -95.45% compared to the previous year's $9.99 million. Losses were -$105.62 million, -11.81% less than in 2023.

Analyst Summary

According to 7 analysts, the average rating for APLT stock is "Buy." The 12-month stock price target is $6.1, which is an increase of 1,553.12% from the latest price.

Price Target

$6.1

(1,553.12% upside)

Analyst Consensus: Buy